SLU-PP-332 is a synthetic pan-estrogen-related receptor (ERRα/ERRβ/ERRγ) agonist. ERRs cooperate with metabolic transcriptional programs involving PGC-1α and regulate mitochondrial oxidative metabolism. 1. Improves glucose tolerance in obese mice In diet-induced-obesity mouse models, SLU-PP-332 treatment was associated with improved glucose metabolism,…
SLU-PP-332 is a synthetic estrogen-related receptor (ERR) α/β/γ agonist and experimental “exercise mimetic.” Its strongest activity is toward ERRα, a nuclear receptor that regulates mitochondrial metabolism, oxidative muscle function, and exercise-responsive gene expression. Importantly, the evidence for its efficacy is…
SLU-PP-332 is a synthetic small-molecule pan-estrogen-related receptor (ERRα/ERRβ/ERRγ) agonist developed as an experimental “exercise mimetic.” It is a research compound, not an approved medicine or dietary supplement. Recent analytical work has established LC-HRMS/MS methods for identifying the parent compound and…
SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRs)—a family of orphan nuclear receptors involved in regulating mitochondrial activity, oxidative metabolism, fatty-acid utilization, and exercise-responsive gene expression. It is particularly notable because it activates ERRα, ERRβ, and ERRγ,…
SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors (ERRα, ERRβ, and ERRγ). It is primarily a research compound, not an approved drug or dietary supplement. Its main value is as a tool for studying exercise-like metabolic adaptations. 1. Exercise-mimetic…
SLU-PP-332 is a synthetic agonist of the estrogen-related receptors (ERRs), especially ERRα. These are nuclear receptors that regulate genes involved in mitochondrial energy production, fatty-acid oxidation, oxidative phosphorylation, and exercise adaptation. Importantly, despite the name, ERRs are not classical estrogen…
SLU-PP-332 appears to have potentially favorable effects on liver fat and systemic lipid metabolism in mice, but the evidence is still preclinical. Importantly, SLU-PP-332 is an ERRα/β/γ agonist, not a PPAR agonist, so PPAR findings should be treated as mechanistic…
SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptor (ERR) family, particularly ERRα. It is best known as an experimental “exercise-mimetic” compound because preclinical studies suggest that activating ERR signaling can reproduce some molecular and metabolic adaptations associated with…
SLU-PP-332 is an experimental exercise-mimetic compound that activates the estrogen-related receptors ERRα, ERRβ, and ERRγ, with particularly strong activity at ERRα. It is being investigated primarily as a research tool and potential metabolic therapeutic—not as an approved human drug. Main…